{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:15:20Z","timestamp":1784589320910,"version":"3.55.0"},"reference-count":167,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40263-025-01230-3","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T05:21:59Z","timestamp":1758777719000},"page":"1273-1295","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sodium\u2013Glucose Cotransporter 2 Inhibitors: An Emerging Therapeutic Approach for Ischemic Stroke Management"],"prefix":"10.1007","volume":"39","author":[{"given":"Yiwei","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8652-4283","authenticated-orcid":false,"given":"Changxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"issue":"6","key":"1230_CR1","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/j.1755-5949.2011.00292.x","volume":"18","author":"PH Chen","year":"2012","unstructured":"Chen PH, et al. Classifying ischemic stroke, from TOAST to CISS. CNS Neurosci Ther. 2012;18(6):452\u20136. https:\/\/doi.org\/10.1111\/j.1755-5949.2011.00292.x.","journal-title":"CNS Neurosci Ther"},{"issue":"2","key":"1230_CR2","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/jmri.27614","volume":"54","author":"X Li","year":"2021","unstructured":"Li X, et al. Association of type 2 diabetes mellitus and glycemic control with intracranial plaque characteristics in patients with acute ischemic stroke. J Magn Reson Imaging. 2021;54(2):655\u201366. https:\/\/doi.org\/10.1002\/jmri.27614.","journal-title":"J Magn Reson Imaging"},{"issue":"4","key":"1230_CR3","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1001\/jamacardio.2016.5224","volume":"2","author":"A Plitt","year":"2017","unstructured":"Plitt A, McGuire DK, Giugliano RP. Atrial fibrillation, type 2 diabetes, and non-vitamin K antagonist oral anticoagulants: a review. JAMA Cardiol. 2017;2(4):442\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2016.5224.","journal-title":"JAMA Cardiol"},{"issue":"2","key":"1230_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10557-021-07249-0","volume":"37","author":"T Koufakis","year":"2023","unstructured":"Koufakis T, et al. Sodium-glucose co-transporter 2 inhibitors versus metformin as the first-line treatment for type 2 diabetes: is it time for a revolution? Cardiovasc Drugs Ther. 2023;37(2):315\u201321. https:\/\/doi.org\/10.1007\/s10557-021-07249-0.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"1230_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-93483-7","volume":"15","author":"W Dai","year":"2025","unstructured":"Dai W, et al. Empagliflozin demonstrates neuroprotective and cardioprotective effects by reducing ischemia\/reperfusion damage in rat models of ischemic stroke and myocardial infarction. Sci Rep. 2025;15(1):8986. https:\/\/doi.org\/10.1038\/s41598-025-93483-7.","journal-title":"Sci Rep"},{"issue":"5","key":"1230_CR6","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1093\/cvr\/cvaf026","volume":"121","author":"G Liu","year":"2025","unstructured":"Liu G, et al. Pre-ischaemic empagliflozin treatment attenuates blood-brain barrier disruption via \u03b2-catenin mediated protection of cerebral endothelial cells. Cardiovasc Res. 2025;121(5):788\u2013802. https:\/\/doi.org\/10.1093\/cvr\/cvaf026.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"1230_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-022-03605-4","volume":"5","author":"M Takashima","year":"2022","unstructured":"Takashima M, et al. Low-dose sodium-glucose cotransporter 2 inhibitor ameliorates ischemic brain injury in mice through pericyte protection without glucose-lowering effects. Commun Biol. 2022;5(1):653. https:\/\/doi.org\/10.1038\/s42003-022-03605-4.","journal-title":"Commun Biol"},{"key":"1230_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cells12182221","author":"B Shim","year":"2023","unstructured":"Shim B, et al. Canagliflozin, an inhibitor of the NA(+)-coupled D-glucose cotransporter, sglt2, inhibits astrocyte swelling and brain swelling in cerebral ischemia. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12182221.","journal-title":"Cells"},{"issue":"5","key":"1230_CR9","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/fcp.12548","volume":"34","author":"EF Amin","year":"2020","unstructured":"Amin EF, Rifaai RA, Abdel-latif RG. Empagliflozin attenuates transient cerebral ischemia\/reperfusion injury in hyperglycemic rats via repressing oxidative\u2013inflammatory\u2013apoptotic pathway. Fundam Clin Pharmacol. 2020;34(5):548\u201358. https:\/\/doi.org\/10.1111\/fcp.12548.","journal-title":"Fundam Clin Pharmacol"},{"key":"1230_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.taap.2017.08.005","volume":"333","author":"P Sa-nguanmoo","year":"2017","unstructured":"Sa-nguanmoo P, et al. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats. Toxicol Appl Pharmacol. 2017;333:43\u201350. https:\/\/doi.org\/10.1016\/j.taap.2017.08.005.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"5","key":"1230_CR11","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s12272-020-01237-y","volume":"43","author":"RG Abdel-Latif","year":"2020","unstructured":"Abdel-Latif RG, Rifaai RA, Amin EF. Empagliflozin alleviates neuronal apoptosis induced by cerebral ischemia\/reperfusion injury through HIF-1\u03b1\/VEGF signaling pathway. Arch Pharm Res. 2020;43(5):514\u201325. https:\/\/doi.org\/10.1007\/s12272-020-01237-y.","journal-title":"Arch Pharm Res"},{"issue":"1","key":"1230_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02174-6","volume":"23","author":"E Vercalsteren","year":"2024","unstructured":"Vercalsteren E, et al. The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice. Cardiovasc Diabetol. 2024;23(1):88. https:\/\/doi.org\/10.1186\/s12933-024-02174-6.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"1230_CR13","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2907265","volume":"29","author":"A Simanenkova","year":"2024","unstructured":"Simanenkova A, et al. Microglia involvement into acute and chronic brain damage in diabetic rats: impact of GLP-1RA and SGLT-2i. Front Biosci Landmark. 2024;29(7):265. https:\/\/doi.org\/10.31083\/j.fbl2907265.","journal-title":"Front Biosci Landmark"},{"issue":"2","key":"1230_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244689","volume":"16","author":"CX Li","year":"2021","unstructured":"Li CX, et al. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: a real-world systematic review and meta-analysis. PLoS ONE. 2021;16(2):e0244689. https:\/\/doi.org\/10.1371\/journal.pone.0244689.","journal-title":"PLoS ONE"},{"issue":"2","key":"1230_CR15","doi-asserted-by":"publisher","first-page":"312","DOI":"10.4093\/dmj.2022.0421","volume":"48","author":"JS Kim","year":"2024","unstructured":"Kim JS, et al. Comparative effect of glucose-lowering drugs for type 2 diabetes mellitus on stroke prevention: a systematic review and network meta-analysis. Diabetes Metab J. 2024;48(2):312\u201320. https:\/\/doi.org\/10.4093\/dmj.2022.0421.","journal-title":"Diabetes Metab J"},{"issue":"1","key":"1230_CR16","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.037207","volume":"14","author":"PY Ng","year":"2025","unstructured":"Ng PY, et al. Atherothrombotic outcomes after sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: a territory-wide retrospective cohort study. J Am Heart Assoc. 2025;14(1):e037207. https:\/\/doi.org\/10.1161\/JAHA.124.037207.","journal-title":"J Am Heart Assoc"},{"key":"1230_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1443175","volume":"15","author":"H Kim","year":"2024","unstructured":"Kim H, et al. Comparing ischemic cardiovascular effectiveness and safety between individual SGLT-2 inhibitors and DPP-4 inhibitors in patients with type 2 diabetes: a nationwide population-based cohort study. Front Pharmacol. 2024;15:1443175. https:\/\/doi.org\/10.3389\/fphar.2024.1443175.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1230_CR18","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10557-022-07319-x","volume":"37","author":"S Lee","year":"2023","unstructured":"Lee S, et al. Comparison of sodium-glucose cotransporter-2 inhibitor and dipeptidyl peptidase-4 inhibitor on the risks of new-onset atrial fibrillation, stroke and mortality in diabetic patients: a propensity score-matched study in Hong Kong. Cardiovasc Drugs Ther. 2023;37(3):561\u20139. https:\/\/doi.org\/10.1007\/s10557-022-07319-x.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"1230_CR19","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1001\/jamainternmed.2024.7357","volume":"185","author":"H Shin","year":"2025","unstructured":"Shin H, et al. Comparative effectiveness of individual sodium-glucose cotransporter 2 inhibitors. JAMA Intern Med. 2025;185(3):302. https:\/\/doi.org\/10.1001\/jamainternmed.2024.7357.","journal-title":"JAMA Intern Med"},{"issue":"2","key":"1230_CR20","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1002\/ehf2.15036","volume":"12","author":"MA Bantounou","year":"2025","unstructured":"Bantounou MA, et al. Meta-analysis of sotagliflozin, a dual sodium-glucose-cotransporter 1\/2 inhibitor, for heart failure in type 2 diabetes. ESC Heart Fail. 2025;12(2):968\u201379. https:\/\/doi.org\/10.1002\/ehf2.15036.","journal-title":"ESC Heart Fail"},{"key":"1230_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2024.107730","author":"E Pasqualotto","year":"2024","unstructured":"Pasqualotto E, et al. The effect of sodium-glucose transporter 2 inhibitors on stroke in patients with type 2 diabetes: a meta-analysis. J Stroke Cerebrovasc Dis. 2024. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2024.107730.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"10","key":"1230_CR22","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1111\/dom.15804","volume":"26","author":"TY Chen","year":"2024","unstructured":"Chen TY, et al. Comparing clinical outcomes in patients with type 2 diabetes mellitus after ischaemic stroke: sodium-glucose cotransporter 2 inhibitors users versus non-users. A propensity score matching national cohort study. Diabetes Obes Metab. 2024;26(10):4501\u20139. https:\/\/doi.org\/10.1111\/dom.15804.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1230_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101582","volume":"48","author":"K Fatima","year":"2023","unstructured":"Fatima K, et al. The effect of sodium-glucose co-transporter 2 inhibitors on stroke and atrial fibrillation: a systematic review and meta-analysis. Curr Probl Cardiol. 2023;48(4):101582. https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101582.","journal-title":"Curr Probl Cardiol"},{"issue":"5","key":"1230_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2021.105708","volume":"30","author":"F Barkas","year":"2021","unstructured":"Barkas F, et al. Sodium-glucose cotransporter-2 inhibitors and protection against stroke in patients with type 2 diabetes and impaired renal function: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2021;30(5):105708. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2021.105708.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"5","key":"1230_CR25","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1161\/STROKEAHA.120.031623","volume":"52","author":"Z Zhou","year":"2021","unstructured":"Zhou Z, et al. Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: results from the CREDENCE trial and meta-analysis. Stroke. 2021;52(5):1545\u201356. https:\/\/doi.org\/10.1161\/STROKEAHA.120.031623.","journal-title":"Stroke"},{"issue":"1","key":"1230_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02478-7","volume":"23","author":"Y Mori","year":"2024","unstructured":"Mori Y, et al. Sodium-glucose cotransporter 2 inhibitors and cardiovascular events among patients with type 2 diabetes and low-to-normal body mass index: a nationwide cohort study. Cardiovasc Diabetol. 2024;23(1):372. https:\/\/doi.org\/10.1186\/s12933-024-02478-7.","journal-title":"Cardiovasc Diabetol"},{"key":"1230_CR27","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.2147\/DDDT.S388823","volume":"16","author":"Q Zuo","year":"2022","unstructured":"Zuo Q, et al. Canagliflozin attenuates hepatic steatosis and atherosclerosis progression in western diet-fed ApoE-knockout mice. Drug Des Devel Ther. 2022;16:4161\u201377. https:\/\/doi.org\/10.2147\/DDDT.S388823.","journal-title":"Drug Des Devel Ther"},{"key":"1230_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18081704","author":"Y Nakatsu","year":"2017","unstructured":"Nakatsu Y, et al. The SGLT2 inhibitor luseogliflozin rapidly normalizes aortic mRNA levels of inflammation-related but not lipid-metabolism-related genes and suppresses atherosclerosis in diabetic ApoE KO mice. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18081704.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1230_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-018-0695-y","volume":"17","author":"C Irace","year":"2018","unstructured":"Irace C, et al. Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy. Cardiovasc Diabetol. 2018;17(1):52. https:\/\/doi.org\/10.1186\/s12933-018-0695-y.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1230_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02368-y","volume":"23","author":"T Zhang","year":"2024","unstructured":"Zhang T, et al. Longitudinal assessment of coronary plaque regression related to sodium-glucose cotransporter-2 inhibitor using coronary computed tomography angiography. Cardiovasc Diabetol. 2024;23(1):267. https:\/\/doi.org\/10.1186\/s12933-024-02368-y.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1230_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-016-0449-7","volume":"15","author":"A Tanaka","year":"2016","unstructured":"Tanaka A, et al. Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study. Cardiovasc Diabetol. 2016;15(1):133. https:\/\/doi.org\/10.1186\/s12933-016-0449-7.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1230_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01814-7","volume":"22","author":"C Sardu","year":"2023","unstructured":"Sardu C, et al. SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis. Cardiovasc Diabetol. 2023;22(1):80. https:\/\/doi.org\/10.1186\/s12933-023-01814-7.","journal-title":"Cardiovasc Diabetol"},{"key":"1230_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101337","volume":"54","author":"N D'Onofrio","year":"2021","unstructured":"D\u2019Onofrio N, et al. Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of sodium-glucose co-transporter2 inhibitor treatment. Mol Metab. 2021;54:101337. https:\/\/doi.org\/10.1016\/j.molmet.2021.101337.","journal-title":"Mol Metab"},{"key":"1230_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173040","volume":"875","author":"B Ganbaatar","year":"2020","unstructured":"Ganbaatar B, et al. Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice. Eur J Pharmacol. 2020;875:173040. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173040.","journal-title":"Eur J Pharmacol"},{"issue":"18","key":"1230_CR35","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1093\/cvr\/cvae016","volume":"119","author":"DC Terenzi","year":"2024","unstructured":"Terenzi DC, et al. Restoration of blood vessel regeneration in the era of combination SGLT2i and GLP-1RA therapy for diabetes and obesity. Cardiovasc Res. 2024;119(18):2858\u201374. https:\/\/doi.org\/10.1093\/cvr\/cvae016.","journal-title":"Cardiovasc Res"},{"key":"1230_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.992937","volume":"13","author":"L Yang","year":"2022","unstructured":"Yang L, Zhang X, Wang Q. Effects and mechanisms of SGLT2 inhibitors on the NLRP3 inflammasome, with a focus on atherosclerosis. Front Endocrinol. 2022;13:992937. https:\/\/doi.org\/10.3389\/fendo.2022.992937.","journal-title":"Front Endocrinol"},{"key":"1230_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/nu15102294","author":"D Kounatidis","year":"2023","unstructured":"Kounatidis D, et al. SGLT-2 inhibitors and the inflammasome: what\u2019s next in the 21st century? Nutrients. 2023. https:\/\/doi.org\/10.3390\/nu15102294.","journal-title":"Nutrients"},{"issue":"11","key":"1230_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0143396","volume":"10","author":"M Terasaki","year":"2015","unstructured":"Terasaki M, et al. Amelioration of hyperglycemia with a sodium-glucose cotransporter 2 inhibitor prevents macrophage-driven atherosclerosis through macrophage foam cell formation suppression in type 1 and type 2 diabetic mice. PLoS ONE. 2015;10(11):e0143396. https:\/\/doi.org\/10.1371\/journal.pone.0143396.","journal-title":"PLoS ONE"},{"key":"1230_CR39","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ijcard.2022.07.048","volume":"367","author":"J Fu","year":"2022","unstructured":"Fu J, et al. Empagliflozin inhibits macrophage inflammation through AMPK signaling pathway and plays an anti-atherosclerosis role. Int J Cardiol. 2022;367:56\u201362. https:\/\/doi.org\/10.1016\/j.ijcard.2022.07.048.","journal-title":"Int J Cardiol"},{"key":"1230_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174715","volume":"918","author":"E Abdollahi","year":"2022","unstructured":"Abdollahi E, et al. Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-\u03baB activation in human endothelial cells and differentiated macrophages. Eur J Pharmacol. 2022;918:174715. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174715.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"1230_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01016-5","volume":"19","author":"V Spigoni","year":"2020","unstructured":"Spigoni V, et al. Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events. Cardiovasc Diabetol. 2020;19(1):46. https:\/\/doi.org\/10.1186\/s12933-020-01016-5.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"1230_CR42","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1007\/s00125-021-05498-0","volume":"64","author":"C Kohlmorgen","year":"2021","unstructured":"Kohlmorgen C, et al. Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus. Diabetologia. 2021;64(8):1834\u201349. https:\/\/doi.org\/10.1007\/s00125-021-05498-0.","journal-title":"Diabetologia"},{"issue":"10","key":"1230_CR43","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1007\/s00380-020-01621-0","volume":"35","author":"T Hashikata","year":"2020","unstructured":"Hashikata T, et al. Empagliflozin attenuates neointimal hyperplasia after drug-eluting-stent implantation in patients with type 2 diabetes. Heart Vessels. 2020;35(10):1378\u201389. https:\/\/doi.org\/10.1007\/s00380-020-01621-0.","journal-title":"Heart Vessels"},{"key":"1230_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175826","volume":"954","author":"W Zhang","year":"2023","unstructured":"Zhang W, et al. Empagliflozin inhibits neointimal hyperplasia through attenuating endothelial-to-mesenchymal transition via TAK-1\/NF-\u03baB pathway. Eur J Pharmacol. 2023;954:175826. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175826.","journal-title":"Eur J Pharmacol"},{"key":"1230_CR45","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.bbrc.2023.01.084","volume":"653","author":"Z Wang","year":"2023","unstructured":"Wang Z, et al. Canagliflozin ameliorates epithelial-mesenchymal transition in high-salt diet-induced hypertensive renal injury through restoration of sirtuin 3 expression and the reduction of oxidative stress. Biochem Biophys Res Commun. 2023;653:53\u201361. https:\/\/doi.org\/10.1016\/j.bbrc.2023.01.084.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1230_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0947-5","volume":"18","author":"Y Mori","year":"2019","unstructured":"Mori Y, et al. Luseogliflozin attenuates neointimal hyperplasia after wire injury in high-fat diet-fed mice via inhibition of perivascular adipose tissue remodeling. Cardiovasc Diabetol. 2019;18(1):143. https:\/\/doi.org\/10.1186\/s12933-019-0947-5.","journal-title":"Cardiovasc Diabetol"},{"key":"1230_CR47","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jns.2019.06.007","volume":"403","author":"AT Bjerkreim","year":"2019","unstructured":"Bjerkreim AT, et al. Five-year readmission and mortality differ by ischemic stroke subtype. J Neurol Sci. 2019;403:31\u20137. https:\/\/doi.org\/10.1016\/j.jns.2019.06.007.","journal-title":"J Neurol Sci"},{"issue":"4","key":"1230_CR48","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s11883-006-0009-9","volume":"8","author":"B Murtagh","year":"2006","unstructured":"Murtagh B, Smalling RW. Cardioembolic stroke. Curr Atheroscler Rep. 2006;8(4):310\u20136. https:\/\/doi.org\/10.1007\/s11883-006-0009-9.","journal-title":"Curr Atheroscler Rep"},{"issue":"10","key":"1230_CR49","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1111\/dom.14772","volume":"24","author":"C Li","year":"2022","unstructured":"Li C, et al. Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: a secondary analysis from the CANVAS program and CREDENCE trial and meta-analysis. Diabetes Obes Metab. 2022;24(10):1927\u201338. https:\/\/doi.org\/10.1111\/dom.14772.","journal-title":"Diabetes Obes Metab"},{"key":"1230_CR50","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euae054","author":"A Fichadiya","year":"2024","unstructured":"Fichadiya A, et al. Association between sodium-glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation. Europace. 2024. https:\/\/doi.org\/10.1093\/europace\/euae054.","journal-title":"Europace"},{"issue":"17","key":"1230_CR51","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022222","volume":"10","author":"AK Pandey","year":"2021","unstructured":"Pandey AK, et al. Sodium-glucose co-transporter inhibitors and atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2021;10(17):e022222. https:\/\/doi.org\/10.1161\/JAHA.121.022222.","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"1230_CR52","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.jacep.2022.08.004","volume":"8","author":"H Kishima","year":"2022","unstructured":"Kishima H, et al. Efficacy of sodium-glucose cotransporter 2 inhibitors on outcomes after catheter ablation for atrial fibrillation. JACC Clin Electrophysiol. 2022;8(11):1393\u2013404. https:\/\/doi.org\/10.1016\/j.jacep.2022.08.004.","journal-title":"JACC Clin Electrophysiol"},{"key":"1230_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2025.133083","volume":"426","author":"MZ Ameer","year":"2025","unstructured":"Ameer MZ, et al. Cardiovascular outcomes with SGLT-2 inhibitors in individuals with diabetes and co-existing atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol. 2025;426:133083. https:\/\/doi.org\/10.1016\/j.ijcard.2025.133083.","journal-title":"Int J Cardiol"},{"key":"1230_CR54","doi-asserted-by":"publisher","DOI":"10.1111\/jce.16739","author":"GK Lim","year":"2025","unstructured":"Lim GK, et al. Sodium-glucose cotransporter-2 inhibitors and stroke risk in patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2025. https:\/\/doi.org\/10.1111\/jce.16739.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"1","key":"1230_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02557-9","volume":"24","author":"S-K Chua","year":"2025","unstructured":"Chua S-K, et al. Age-dependent effects of SGLT2 inhibitors on stroke risk in geriatric patients with diabetes and atrial fibrillation. Cardiovasc Diabetol. 2025;24(1):27. https:\/\/doi.org\/10.1186\/s12933-024-02557-9.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"1230_CR56","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1111\/dom.16147","volume":"27","author":"H Tang","year":"2025","unstructured":"Tang H, et al. Assessing the benefit\u2013risk profile of newer glucose-lowering drugs: a systematic review and network meta-analysis of randomized outcome trials. Diabetes Obes Metab. 2025;27(3):1444\u201355. https:\/\/doi.org\/10.1111\/dom.16147.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1230_CR57","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/dom.14854","volume":"25","author":"AM Fawzy","year":"2023","unstructured":"Fawzy AM, et al. Incident heart failure, arrhythmias and cardiovascular outcomes with sodium-glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: insights from a global federated electronic medical record database. Diabetes Obes Metab. 2023;25(2):602\u201310. https:\/\/doi.org\/10.1111\/dom.14854.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1230_CR58","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/jce.16544","volume":"36","author":"NA Abdelhadi","year":"2025","unstructured":"Abdelhadi NA, et al. Impact of sodium-glucose co-transporter 2 inhibitors on atrial fibrillation recurrence post-catheter ablation among patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Cardiovasc Electrophysiol. 2025;36(3):673\u201382. https:\/\/doi.org\/10.1111\/jce.16544.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"2","key":"1230_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0314454","volume":"20","author":"Y Cho","year":"2025","unstructured":"Cho Y, et al. The effect of SGLT2 inhibitor in patients with type 2 diabetes and atrial fibrillation. PLoS ONE. 2025;20(2):e0314454. https:\/\/doi.org\/10.1371\/journal.pone.0314454.","journal-title":"PLoS ONE"},{"issue":"2","key":"1230_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3775","volume":"40","author":"YY Chen","year":"2024","unstructured":"Chen YY, et al. The impact of sodium-glucose co-transporter-2 inhibitors on dementia and cardiovascular events in diabetic patients with atrial fibrillation. Diabetes Metab Res Rev. 2024;40(2):e3775. https:\/\/doi.org\/10.1002\/dmrr.3775.","journal-title":"Diabetes Metab Res Rev"},{"issue":"10","key":"1230_CR61","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.027764","volume":"12","author":"SN Chang","year":"2023","unstructured":"Chang SN, et al. Sodium-glucose cotransporter-2 inhibitor prevents stroke in patients with diabetes and atrial fibrillation. J Am Heart Assoc. 2023;12(10):e027764. https:\/\/doi.org\/10.1161\/JAHA.122.027764.","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"1230_CR62","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1152\/physrev.00055.2009","volume":"91","author":"EM Wright","year":"2011","unstructured":"Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91(2):733\u201394. https:\/\/doi.org\/10.1152\/physrev.00055.2009.","journal-title":"Physiol Rev"},{"issue":"19","key":"1230_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197230","volume":"21","author":"Y Chiba","year":"2020","unstructured":"Chiba Y, et al. Glucose, fructose, and urate transporters in the choroid plexus epithelium. Int J Mol Sci. 2020;21(19):7230. https:\/\/doi.org\/10.3390\/ijms21197230.","journal-title":"Int J Mol Sci"},{"key":"1230_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26237213","author":"A Pawlos","year":"2021","unstructured":"Pawlos A, et al. Neuroprotective effect of SGLT2 inhibitors. Molecules. 2021. https:\/\/doi.org\/10.3390\/molecules26237213.","journal-title":"Molecules"},{"issue":"10","key":"1230_CR65","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40265-019-01148-3","volume":"79","author":"S Dhillon","year":"2019","unstructured":"Dhillon S. Dapagliflozin: a review in type 2 diabetes. Drugs. 2019;79(10):1135\u201346. https:\/\/doi.org\/10.1007\/s40265-019-01148-3.","journal-title":"Drugs"},{"key":"1230_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/diseases8020014","author":"Y Saisho","year":"2020","unstructured":"Saisho Y. SGLT2 inhibitors: the star in the treatment of type 2 diabetes? Diseases. 2020. https:\/\/doi.org\/10.3390\/diseases8020014.","journal-title":"Diseases"},{"key":"1230_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.777861","volume":"8","author":"JI Fonseca-Correa","year":"2021","unstructured":"Fonseca-Correa JI, Correa-Rotter R. Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review. Front Med. 2021;8:777861. https:\/\/doi.org\/10.3389\/fmed.2021.777861.","journal-title":"Front Med"},{"issue":"1","key":"1230_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01512-w","volume":"21","author":"B Xu","year":"2022","unstructured":"Xu B, et al. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Cardiovasc Diabetol. 2022;21(1):83. https:\/\/doi.org\/10.1186\/s12933-022-01512-w.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"1230_CR69","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1007\/s12035-018-1195-5","volume":"56","author":"S Rom","year":"2019","unstructured":"Rom S, et al. Hyperglycemia-driven neuroinflammation compromises BBB leading to memory loss in both diabetes mellitus (DM) type 1 and type 2 mouse models. Mol Neurobiol. 2019;56(3):1883\u201396. https:\/\/doi.org\/10.1007\/s12035-018-1195-5.","journal-title":"Mol Neurobiol"},{"issue":"1","key":"1230_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-35576-0","volume":"8","author":"MA M\u00e4e","year":"2018","unstructured":"M\u00e4e MA, et al. Prolonged systemic hyperglycemia does not cause pericyte loss and permeability at the mouse blood-brain barrier. Sci Rep. 2018;8(1):17462. https:\/\/doi.org\/10.1038\/s41598-018-35576-0.","journal-title":"Sci Rep"},{"issue":"1","key":"1230_CR71","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/nyas.14583","volume":"1495","author":"MJ Krinock","year":"2021","unstructured":"Krinock MJ, Singhal NS. Diabetes, stroke, and neuroresilience: looking beyond hyperglycemia. Ann N Y Acad Sci. 2021;1495(1):78\u201398. https:\/\/doi.org\/10.1111\/nyas.14583.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"1230_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02734-4","volume":"24","author":"S Delalat","year":"2025","unstructured":"Delalat S, et al. Dysregulated inflammation, oxidative stress, and protein quality control in diabetic HFpEF: unraveling mechanisms and therapeutic targets. Cardiovasc Diabetol. 2025;24(1):211. https:\/\/doi.org\/10.1186\/s12933-025-02734-4.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"1230_CR73","doi-asserted-by":"publisher","first-page":"421","DOI":"10.7326\/0003-4819-141-6-200409210-00007","volume":"141","author":"E Selvin","year":"2004","unstructured":"Selvin E, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141(6):421\u201331. https:\/\/doi.org\/10.7326\/0003-4819-141-6-200409210-00007.","journal-title":"Ann Intern Med"},{"issue":"8","key":"1230_CR74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042551","volume":"7","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, et al. Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS ONE. 2012;7(8):e42551. https:\/\/doi.org\/10.1371\/journal.pone.0042551.","journal-title":"PLoS ONE"},{"issue":"2","key":"1230_CR75","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/jth.15154","volume":"19","author":"F Denorme","year":"2021","unstructured":"Denorme F, et al. Hyperglycemia exacerbates ischemic stroke outcome independent of platelet glucose uptake. J Thromb Haemost. 2021;19(2):536\u201346. https:\/\/doi.org\/10.1111\/jth.15154.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"1230_CR76","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s13105-018-0632-2","volume":"74","author":"E Baranovicova","year":"2018","unstructured":"Baranovicova E, et al. NMR metabolomic study of blood plasma in ischemic and ischemically preconditioned rats: an increased level of ketone bodies and decreased content of glycolytic products 24 h after global cerebral ischemia. J Physiol Biochem. 2018;74(3):417\u201329. https:\/\/doi.org\/10.1007\/s13105-018-0632-2.","journal-title":"J Physiol Biochem"},{"issue":"2","key":"1230_CR77","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/cc10020","volume":"15","author":"H White","year":"2011","unstructured":"White H, Venkatesh B. Clinical review: ketones and brain injury. Crit Care. 2011;15(2):219. https:\/\/doi.org\/10.1186\/cc10020.","journal-title":"Crit Care"},{"issue":"5 Pt 1","key":"1230_CR78","doi-asserted-by":"publisher","first-page":"E746","DOI":"10.1152\/ajpendo.1996.270.5.E746","volume":"270","author":"SG Hasselbalch","year":"1996","unstructured":"Hasselbalch SG, et al. Changes in cerebral blood flow and carbohydrate metabolism during acute hyperketonemia. Am J Physiol. 1996;270(5 Pt 1):E746\u201351. https:\/\/doi.org\/10.1152\/ajpendo.1996.270.5.E746.","journal-title":"Am J Physiol"},{"issue":"2","key":"1230_CR79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190556","volume":"13","author":"M Svart","year":"2018","unstructured":"Svart M, et al. Regional cerebral effects of ketone body infusion with 3-hydroxybutyrate in humans: reduced glucose uptake, unchanged oxygen consumption and increased blood flow by positron emission tomography. A randomized, controlled trial. PLoS ONE. 2018;13(2):e0190556. https:\/\/doi.org\/10.1371\/journal.pone.0190556.","journal-title":"PLoS ONE"},{"issue":"18","key":"1230_CR80","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","volume":"146","author":"M Packer","year":"2022","unstructured":"Packer M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis. Circulation. 2022;146(18):1383\u2013405. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061732.","journal-title":"Circulation"},{"key":"1230_CR81","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2023-003666","author":"E Chow","year":"2023","unstructured":"Chow E, Clement S, Garg R. Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors. BMJ Open Diabetes Res Care. 2023. https:\/\/doi.org\/10.1136\/bmjdrc-2023-003666.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"21","key":"1230_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/cells11213372","volume":"11","author":"KI Avgerinos","year":"2022","unstructured":"Avgerinos KI, et al. Empagliflozin induced ketosis, upregulated IGF-1\/insulin receptors and the canonical insulin signaling pathway in neurons, and decreased the excitatory neurotransmitter glutamate in the brain of non-diabetics. Cells. 2022;11(21):3372. https:\/\/doi.org\/10.3390\/cells11213372.","journal-title":"Cells"},{"issue":"7","key":"1230_CR83","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s00702-008-0050-7","volume":"115","author":"KK Tai","year":"2008","unstructured":"Tai KK, et al. Ketogenic diet prevents cardiac arrest-induced cerebral ischemic neurodegeneration. J Neural Transm. 2008;115(7):1011\u20137. https:\/\/doi.org\/10.1007\/s00702-008-0050-7.","journal-title":"J Neural Transm"},{"issue":"4","key":"1230_CR84","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.12.024","volume":"28","author":"S Shaafi","year":"2019","unstructured":"Shaafi S, et al. Early motor-behavioral outcome of ischemic stroke with ketogenic diet preconditioning: interventional animal study. J Stroke Cerebrovasc Dis. 2019;28(4):1032\u20139. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2018.12.024.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"1","key":"1230_CR85","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1254\/jjp.89.36","volume":"89","author":"M Suzuki","year":"2002","unstructured":"Suzuki M, et al. Beta-hydroxybutyrate, a cerebral function improving agent, protects rat brain against ischemic damage caused by permanent and transient focal cerebral ischemia. Jpn J Pharmacol. 2002;89(1):36\u201343. https:\/\/doi.org\/10.1254\/jjp.89.36.","journal-title":"Jpn J Pharmacol"},{"issue":"4","key":"1230_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112294","volume":"42","author":"Y-H Lin","year":"2023","unstructured":"Lin Y-H, et al. Ketone bodies promote stroke recovery via GAT-1-dependent cortical network remodeling. Cell Rep. 2023;42(4):112294. https:\/\/doi.org\/10.1016\/j.celrep.2023.112294.","journal-title":"Cell Rep"},{"key":"1230_CR87","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.15092","author":"SF Sleiman","year":"2016","unstructured":"Sleiman SF, et al. Exercise promotes the expression of brain derived neurotrophic factor (BDNF) through the action of the ketone body \u03b2-hydroxybutyrate. Elife. 2016. https:\/\/doi.org\/10.7554\/eLife.15092.","journal-title":"Elife"},{"issue":"1","key":"1230_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010124","volume":"25","author":"J Jang","year":"2023","unstructured":"Jang J, et al. Molecular mechanisms of neuroprotection by ketone bodies and ketogenic diet in cerebral ischemia and neurodegenerative diseases. Int J Mol Sci. 2023;25(1):124. https:\/\/doi.org\/10.3390\/ijms25010124.","journal-title":"Int J Mol Sci"},{"key":"1230_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115710","author":"AP Gureev","year":"2024","unstructured":"Gureev AP, et al. Beta-hydroxybutyrate mitigates sensorimotor and cognitive impairments in a photothrombosis-induced ischemic stroke in mice. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25115710.","journal-title":"Int J Mol Sci"},{"issue":"17","key":"1230_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713289","volume":"24","author":"SAH Metwally","year":"2023","unstructured":"Metwally SAH, et al. Pharmacological inhibition of NHE1 protein increases white matter resilience and neurofunctional recovery after ischemic stroke. Int J Mol Sci. 2023;24(17):13289. https:\/\/doi.org\/10.3390\/ijms241713289.","journal-title":"Int J Mol Sci"},{"issue":"19","key":"1230_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/cells11193107","volume":"11","author":"M Heimke","year":"2022","unstructured":"Heimke M, et al. Anti-inflammatory properties of the SGLT2 inhibitor empagliflozin in activated primary microglia. Cells. 2022;11(19):3107. https:\/\/doi.org\/10.3390\/cells11193107.","journal-title":"Cells"},{"issue":"7","key":"1230_CR92","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2337\/db22-0970","volume":"73","author":"M Yamato","year":"2024","unstructured":"Yamato M, et al. The early pathogenesis of diabetic retinopathy and its attenuation by sodium-glucose transporter 2 inhibitors. Diabetes. 2024;73(7):1153\u201366. https:\/\/doi.org\/10.2337\/db22-0970.","journal-title":"Diabetes"},{"key":"1230_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109293","volume":"223","author":"LH Khedr","year":"2023","unstructured":"Khedr LH, et al. Canagliflozin attenuates chronic unpredictable mild stress induced neuroinflammation via modulating AMPK\/mTOR autophagic signaling. Neuropharmacology. 2023;223:109293. https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109293.","journal-title":"Neuropharmacology"},{"issue":"4","key":"1230_CR94","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1159\/000535420","volume":"114","author":"X Chen","year":"2024","unstructured":"Chen X, et al. Dapagliflozin ameliorates ovulation disorders via attenuating activated microglia-mediated hypothalamic inflammation in HFD-fed mice. Neuroendocrinology. 2024;114(4):331\u201347. https:\/\/doi.org\/10.1159\/000535420.","journal-title":"Neuroendocrinology"},{"issue":"1","key":"1230_CR95","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-023-02982-9","volume":"20","author":"Z Yang","year":"2023","unstructured":"Yang Z, et al. Empagliflozin targets Mfn1 and Opa1 to attenuate microglia-mediated neuroinflammation in retinal ischemia and reperfusion injury. J Neuroinflammation. 2023;20(1):296. https:\/\/doi.org\/10.1186\/s12974-023-02982-9.","journal-title":"J Neuroinflammation"},{"issue":"5","key":"1230_CR96","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.tem.2024.02.003","volume":"35","author":"M Mashayekhi","year":"2024","unstructured":"Mashayekhi M, et al. Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors. Trends Endocrinol Metab. 2024;35(5):425\u201338. https:\/\/doi.org\/10.1016\/j.tem.2024.02.003.","journal-title":"Trends Endocrinol Metab"},{"key":"1230_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/9944880","volume":"2021","author":"N Lee","year":"2021","unstructured":"Lee N, et al. Anti-inflammatory effects of empagliflozin and gemigliptin on LPS-stimulated macrophage via the IKK\/NF-\u03baB, MKK7\/JNK, and JAK2\/STAT1 signalling pathways. J Immunol Res. 2021;2021:1\u201311. https:\/\/doi.org\/10.1155\/2021\/9944880.","journal-title":"J Immunol Res"},{"key":"1230_CR98","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jad.2024.05.150","volume":"360","author":"Q Huang","year":"2024","unstructured":"Huang Q, et al. Empagliflozin alleviates neuroinflammation by inhibiting astrocyte activation in the brain and regulating gut microbiota of high-fat diet mice. J Affect Disord. 2024;360:229\u201341. https:\/\/doi.org\/10.1016\/j.jad.2024.05.150.","journal-title":"J Affect Disord"},{"issue":"4","key":"1230_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04831-8","volume":"13","author":"R Liu","year":"2022","unstructured":"Liu R, et al. Nox activation in reactive astrocytes regulates astrocytic LCN2 expression and neurodegeneration. Cell Death Dis. 2022;13(4):371. https:\/\/doi.org\/10.1038\/s41419-022-04831-8.","journal-title":"Cell Death Dis"},{"issue":"21","key":"1230_CR100","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27217174","volume":"27","author":"MM Nakhal","year":"2022","unstructured":"Nakhal MM, et al. Repurposing SGLT2 inhibitors for neurological disorders: a focus on the autism spectrum disorder. Molecules. 2022;27(21):7174. https:\/\/doi.org\/10.3390\/molecules27217174.","journal-title":"Molecules"},{"key":"1230_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.121258","volume":"312","author":"HH Mousa","year":"2023","unstructured":"Mousa HH, Sharawy MH, Nader MA. Empagliflozin enhances neuroplasticity in rotenone-induced parkinsonism: role of BDNF, CREB and Npas4. Life Sci. 2023;312:121258. https:\/\/doi.org\/10.1016\/j.lfs.2022.121258.","journal-title":"Life Sci"},{"issue":"4","key":"1230_CR102","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1021\/acschemneuro.0c00722","volume":"12","author":"HH Arab","year":"2021","unstructured":"Arab HH, Safar MM, Shahin NN. Targeting ROS-dependent AKT\/GSK-3\u03b2\/NF-\u03baB and DJ-1\/Nrf2 pathways by dapagliflozin attenuates neuronal injury and motor dysfunction in rotenone-induced Parkinson\u2019s disease rat model. ACS Chem Neurosci. 2021;12(4):689\u2013703. https:\/\/doi.org\/10.1021\/acschemneuro.0c00722.","journal-title":"ACS Chem Neurosci"},{"issue":"8","key":"1230_CR103","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1161\/HYPERTENSIONAHA.122.19586","volume":"79","author":"P Mone","year":"2022","unstructured":"Mone P, et al. SGLT2 inhibition via empagliflozin improves endothelial function and reduces mitochondrial oxidative stress: insights from frail hypertensive and diabetic patients. Hypertension. 2022;79(8):1633\u201343. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.122.19586.","journal-title":"Hypertension"},{"issue":"2","key":"1230_CR104","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00709-019-01439-2","volume":"257","author":"SS Andrabi","year":"2020","unstructured":"Andrabi SS, Parvez S, Tabassum H. Ischemic stroke and mitochondria: mechanisms and targets. Protoplasma. 2020;257(2):335\u201343. https:\/\/doi.org\/10.1007\/s00709-019-01439-2.","journal-title":"Protoplasma"},{"key":"1230_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.121002","volume":"310","author":"AS Kamel","year":"2022","unstructured":"Kamel AS, et al. Boosting amygdaloid GABAergic and neurotrophic machinery via dapagliflozin-enhanced LKB1\/AMPK signaling in anxious demented rats. Life Sci. 2022;310:121002. https:\/\/doi.org\/10.1016\/j.lfs.2022.121002.","journal-title":"Life Sci"},{"issue":"7","key":"1230_CR106","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s12272-022-01391-5","volume":"45","author":"NF Abdelkader","year":"2022","unstructured":"Abdelkader NF, et al. Empagliflozin mitigates type 2 diabetes-associated peripheral neuropathy: a glucose-independent effect through AMPK signaling. Arch Pharm Res. 2022;45(7):475\u201393. https:\/\/doi.org\/10.1007\/s12272-022-01391-5.","journal-title":"Arch Pharm Res"},{"key":"1230_CR107","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.bbrc.2022.05.022","volume":"615","author":"L He","year":"2022","unstructured":"He L, et al. Dapagliflozin improves endothelial cell dysfunction by regulating mitochondrial production via the SIRT1\/PGC-1\u03b1 pathway in obese mice. Biochem Biophys Res Commun. 2022;615:123\u201330. https:\/\/doi.org\/10.1016\/j.bbrc.2022.05.022.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"1230_CR108","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1161\/strokeaha.113.004188","volume":"45","author":"KM Thierfelder","year":"2014","unstructured":"Thierfelder KM, et al. Vertebral artery hypoplasia: frequency and effect on cerebellar blood flow characteristics. Stroke. 2014;45(5):1363\u20138. https:\/\/doi.org\/10.1161\/strokeaha.113.004188.","journal-title":"Stroke"},{"issue":"9","key":"1230_CR109","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s00424-020-02441-x","volume":"472","author":"H Koepsell","year":"2020","unstructured":"Koepsell H. Glucose transporters in brain in health and disease. Pfl\u00fcgers Arch Eur J Physiol. 2020;472(9):1299\u2013343. https:\/\/doi.org\/10.1007\/s00424-020-02441-x.","journal-title":"Pfl\u00fcgers Arch Eur J Physiol"},{"issue":"1","key":"1230_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04379-z","volume":"13","author":"M Bellut","year":"2021","unstructured":"Bellut M, et al. NLPR3 inflammasome inhibition alleviates hypoxic endothelial cell death in vitro and protects blood-brain barrier integrity in murine stroke. Cell Death Dis. 2021;13(1):20. https:\/\/doi.org\/10.1038\/s41419-021-04379-z.","journal-title":"Cell Death Dis"},{"issue":"2","key":"1230_CR111","doi-asserted-by":"publisher","first-page":"H246","DOI":"10.1152\/ajpheart.00438.2021","volume":"322","author":"S Wang","year":"2022","unstructured":"Wang S, et al. Luseogliflozin, a sodium-glucose cotransporter-2 inhibitor, reverses cerebrovascular dysfunction and cognitive impairments in 18-mo-old diabetic animals. Am J Physiol Heart Circ Physiol. 2022;322(2):H246\u201359. https:\/\/doi.org\/10.1152\/ajpheart.00438.2021.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"5","key":"1230_CR112","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3594\/000000178","volume":"53","author":"L Uthman","year":"2019","unstructured":"Uthman L, et al. Empagliflozin and dapagliflozin reduce ROS generation and restore NO bioavailability in tumor necrosis factor \u03b1-stimulated human coronary arterial endothelial cells. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2019;53(5):865\u201386. https:\/\/doi.org\/10.3594\/000000178.","journal-title":"Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol"},{"issue":"5","key":"1230_CR113","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.kint.2020.12.013","volume":"99","author":"RP Juni","year":"2021","unstructured":"Juni RP, et al. Empagliflozin restores chronic kidney disease-induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction. Kidney Int. 2021;99(5):1088\u2013101. https:\/\/doi.org\/10.1016\/j.kint.2020.12.013.","journal-title":"Kidney Int"},{"issue":"11","key":"1230_CR114","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112394","volume":"9","author":"M Oelze","year":"2014","unstructured":"Oelze M, et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS ONE. 2014;9(11):e112394. https:\/\/doi.org\/10.1371\/journal.pone.0112394.","journal-title":"PLoS ONE"},{"issue":"1","key":"1230_CR115","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-018-0750-8","volume":"17","author":"AR Aroor","year":"2018","unstructured":"Aroor AR, et al. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury. Cardiovasc Diabetol. 2018;17(1):108. https:\/\/doi.org\/10.1186\/s12933-018-0750-8.","journal-title":"Cardiovasc Diabetol"},{"key":"1230_CR116","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2016.00043","volume":"3","author":"HM Salim","year":"2016","unstructured":"Salim HM, et al. Glycemic control with ipragliflozin, a novel selective SGLT2 inhibitor, ameliorated endothelial dysfunction in streptozotocin-induced diabetic mouse. Front Cardiovasc Med. 2016;3:43. https:\/\/doi.org\/10.3389\/fcvm.2016.00043.","journal-title":"Front Cardiovasc Med"},{"key":"1230_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115213","volume":"165","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, et al. Dapagliflozin prevents oxidative stress-induced endothelial dysfunction via sirtuin 1 activation. Biomed Pharmacother. 2023;165:115213. https:\/\/doi.org\/10.1016\/j.biopha.2023.115213.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"1230_CR118","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci9030057","volume":"9","author":"M Hayden","year":"2019","unstructured":"Hayden M, et al. Empagliflozin ameliorates type 2 diabetes-induced ultrastructural remodeling of the neurovascular unit and neuroglia in the female db\/db mouse. Brain Sci. 2019;9(3):57. https:\/\/doi.org\/10.3390\/brainsci9030057.","journal-title":"Brain Sci"},{"issue":"1","key":"1230_CR119","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00210-023-02607-1","volume":"397","author":"M-A Campeau","year":"2024","unstructured":"Campeau M-A, Leask RL. Empagliflozin reduces endoplasmic reticulum stress associated TXNIP\/NLRP3 activation in tunicamycin-stimulated aortic endothelial cells. Naunyn-Schmiedebergs Arch Pharmacol. 2024;397(1):267\u201379. https:\/\/doi.org\/10.1007\/s00210-023-02607-1.","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"1230_CR120","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168786","author":"W Durante","year":"2021","unstructured":"Durante W, Behnammanesh G, Peyton KJ. Effects of sodium-glucose co-transporter 2 inhibitors on vascular cell function and arterial remodeling. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22168786.","journal-title":"Int J Mol Sci"},{"key":"1230_CR121","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25137274","author":"N Mylonas","year":"2024","unstructured":"Mylonas N, et al. Endothelial protection by sodium-glucose cotransporter 2 inhibitors: a literature review of in vitro and in vivo studies. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25137274.","journal-title":"Int J Mol Sci"},{"key":"1230_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2022.107095","volume":"146","author":"C Bruckert","year":"2022","unstructured":"Bruckert C, et al. Empagliflozin prevents angiotensin II-induced hypertension related micro and macrovascular endothelial cell activation and diastolic dysfunction in rats despite persistent hypertension: role of endothelial SGLT1 and 2. Vasc Pharmacol. 2022;146:107095. https:\/\/doi.org\/10.1016\/j.vph.2022.107095.","journal-title":"Vasc Pharmacol"},{"key":"1230_CR123","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158777","author":"KJ Peyton","year":"2022","unstructured":"Peyton KJ, et al. Canagliflozin inhibits human endothelial cell inflammation through the induction of heme oxygenase-1. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23158777.","journal-title":"Int J Mol Sci"},{"key":"1230_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114907","volume":"164","author":"MS Dabour","year":"2023","unstructured":"Dabour MS, et al. Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway. Biomed Pharmacother. 2023;164:114907. https:\/\/doi.org\/10.1016\/j.biopha.2023.114907.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"1230_CR125","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1007\/s13311-021-01140-4","volume":"18","author":"RN Muhammad","year":"2021","unstructured":"Muhammad RN, et al. Crosstalk among NLRP3 inflammasome, ET(B)R signaling, and mirnas in stress-induced depression-like behavior: a modulatory role for SGLT2 inhibitors. Neurotherapeutics. 2021;18(4):2664\u201381. https:\/\/doi.org\/10.1007\/s13311-021-01140-4.","journal-title":"Neurotherapeutics"},{"key":"1230_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176381","volume":"968","author":"Z Liu","year":"2024","unstructured":"Liu Z, et al. Canagliflozin protects against hyperglycemia-induced cerebrovascular injury by preventing blood-brain barrier (BBB) disruption via AMPK\/Sp1\/adenosine A2A receptor. Eur J Pharmacol. 2024;968:176381. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176381.","journal-title":"Eur J Pharmacol"},{"key":"1230_CR127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/2193432","volume":"2017","author":"S Liao","year":"2017","unstructured":"Liao S, et al. Endothelial progenitor cells for ischemic stroke: update on basic research and application. Stem Cells Int. 2017;2017:1\u201312. https:\/\/doi.org\/10.1155\/2017\/2193432.","journal-title":"Stem Cells Int"},{"issue":"3","key":"1230_CR128","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1172\/jci20622","volume":"114","author":"A Taguchi","year":"2004","unstructured":"Taguchi A, et al. Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest. 2004;114(3):330\u20138. https:\/\/doi.org\/10.1172\/jci20622.","journal-title":"J Clin Invest"},{"issue":"9","key":"1230_CR129","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1161\/STROKEAHA.119.025304","volume":"51","author":"SJ Chan","year":"2020","unstructured":"Chan SJ, et al. Vascular endothelial growth factor 165-binding heparan sulfate promotes functional recovery from cerebral ischemia. Stroke. 2020;51(9):2844\u201353. https:\/\/doi.org\/10.1161\/STROKEAHA.119.025304.","journal-title":"Stroke"},{"issue":"5","key":"1230_CR130","doi-asserted-by":"publisher","first-page":"H1210","DOI":"10.1152\/ajpheart.00141.2023","volume":"325","author":"E Bakbak","year":"2023","unstructured":"Bakbak E, et al. Empagliflozin improves circulating vascular regenerative cell content in people without diabetes with risk factors for adverse cardiac remodeling. Am J Physiol Heart Circul Physiol. 2023;325(5):H1210\u201322. https:\/\/doi.org\/10.1152\/ajpheart.00141.2023.","journal-title":"Am J Physiol Heart Circul Physiol"},{"issue":"1","key":"1230_CR131","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01235-4","volume":"20","author":"SR Nandula","year":"2021","unstructured":"Nandula SR, et al. Role of canagliflozin on function of CD34+ve endothelial progenitor cells (EPC) in patients with type 2 diabetes. Cardiovasc Diabetol. 2021;20(1):44. https:\/\/doi.org\/10.1186\/s12933-021-01235-4.","journal-title":"Cardiovasc Diabetol"},{"key":"1230_CR132","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.bbrc.2023.05.094","volume":"671","author":"L Luo","year":"2023","unstructured":"Luo L, et al. Dapagliflozin restores diabetes-associated decline in vasculogenic capacity of endothelial progenitor cells via activating AMPK-mediated inhibition of inflammation and oxidative stress. Biochem Biophys Res Commun. 2023;671:205\u201314. https:\/\/doi.org\/10.1016\/j.bbrc.2023.05.094.","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"1230_CR133","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1210\/jc.2018-00824","volume":"103","author":"BM Bonora","year":"2018","unstructured":"Bonora BM, et al. Effects of SGLT2 inhibitors on circulating stem and progenitor cells in patients with type 2 diabetes. J Clin Endocrinol Metab. 2018;103(10):3773\u201382. https:\/\/doi.org\/10.1210\/jc.2018-00824.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1230_CR134","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.cmet.2019.08.015","volume":"30","author":"DA Hess","year":"2019","unstructured":"Hess DA, et al. SGLT2 inhibition with empagliflozin increases circulating provascular progenitor cells in people with type 2 diabetes mellitus. Cell Metab. 2019;30(4):609\u201313. https:\/\/doi.org\/10.1016\/j.cmet.2019.08.015.","journal-title":"Cell Metab"},{"key":"1230_CR135","doi-asserted-by":"publisher","first-page":"104118","DOI":"10.1016\/j.amsu.2022.104118","volume":"79","author":"BD Pathak","year":"2022","unstructured":"Pathak BD, et al. Euglycemic diabetic ketoacidosis in a patient with acute stroke taking sodium glucose co-transporter 2 inhibitor. Ann Med Surg (2012). 2022;79:104118. https:\/\/doi.org\/10.1016\/j.amsu.2022.104118.","journal-title":"Ann Med Surg (2012)"},{"issue":"10","key":"1230_CR136","doi-asserted-by":"publisher","first-page":"e18629","DOI":"10.7759\/cureus.18629","volume":"13","author":"SA Hussaini","year":"2021","unstructured":"Hussaini SA, et al. Late-onset euglycemic diabetic ketoacidosis in a patient with massive stroke requiring decompressive craniectomy: a case report. Cureus. 2021;13(10):e18629. https:\/\/doi.org\/10.7759\/cureus.18629.","journal-title":"Cureus"},{"issue":"3","key":"1230_CR137","doi-asserted-by":"publisher","first-page":"272","DOI":"10.4239\/wjd.v13.i3.272","volume":"13","author":"A Razok","year":"2022","unstructured":"Razok A, et al. Sodium-glucose co-transporter 2 inhibitors induced euglycemic diabetic ketoacidosis within four days of initiation. World J Diabetes. 2022;13(3):272\u20134. https:\/\/doi.org\/10.4239\/wjd.v13.i3.272.","journal-title":"World J Diabetes"},{"key":"1230_CR138","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejim.2019.03.014","volume":"63","author":"L Barski","year":"2019","unstructured":"Barski L, et al. Euglycemic diabetic ketoacidosis. Eur J Intern Med. 2019;63:9\u201314. https:\/\/doi.org\/10.1016\/j.ejim.2019.03.014.","journal-title":"Eur J Intern Med"},{"issue":"1","key":"1230_CR139","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2337\/dc23-1163","volume":"47","author":"MM Umapathysivam","year":"2024","unstructured":"Umapathysivam MM, et al. Euglycemic ketoacidosis in two patients without diabetes after introduction of sodium-glucose cotransporter 2 inhibitor for heart failure with reduced ejection fraction. Diabetes Care. 2024;47(1):140\u20133. https:\/\/doi.org\/10.2337\/dc23-1163.","journal-title":"Diabetes Care"},{"issue":"9","key":"1230_CR140","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.2337\/dc15-1380","volume":"38","author":"J Rosenstock","year":"2015","unstructured":"Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38(9):1638\u201342. https:\/\/doi.org\/10.2337\/dc15-1380.","journal-title":"Diabetes Care"},{"issue":"2","key":"1230_CR141","doi-asserted-by":"publisher","first-page":"232470961771004","DOI":"10.1177\/2324709617710040","volume":"5","author":"S Pujara","year":"2017","unstructured":"Pujara S, Ioachimescu A. Prolonged ketosis in a patient with euglycemic diabetic ketoacidosis secondary to dapagliflozin. J Investig Med High Impact Case Rep. 2017;5(2):2324709617710040. https:\/\/doi.org\/10.1177\/2324709617710040.","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"3","key":"1230_CR142","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/MBC.0b013e32834fb599","volume":"23","author":"SV Cherian","year":"2012","unstructured":"Cherian SV, et al. Diabetic ketoacidosis complicated by generalized venous thrombosis: a case report and review. Blood Coagul Fibrinolysis. 2012;23(3):238\u201340. https:\/\/doi.org\/10.1097\/MBC.0b013e32834fb599.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"1230_CR143","doi-asserted-by":"publisher","first-page":"59","DOI":"10.17925\/EE.2018.14.1.59","volume":"14","author":"NS Mohd Nor","year":"2018","unstructured":"Mohd Nor NS, et al. Ischaemic haemorrhagic stroke in a child with new onset type 1 diabetes mellitus. Eur Endocrinol. 2018;14(1):59\u201361. https:\/\/doi.org\/10.17925\/EE.2018.14.1.59.","journal-title":"Eur Endocrinol"},{"key":"1230_CR144","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2886","author":"H Qiu","year":"2017","unstructured":"Qiu H, Novikov A, Vallon V. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives. Diabetes Metab Res Rev. 2017. https:\/\/doi.org\/10.1002\/dmrr.2886.","journal-title":"Diabetes Metab Res Rev"},{"issue":"5","key":"1230_CR145","doi-asserted-by":"publisher","first-page":"514","DOI":"10.4239\/wjd.v12.i5.514","volume":"12","author":"P Nasa","year":"2021","unstructured":"Nasa P, et al. Euglycemic diabetic ketoacidosis: a missed diagnosis. World J Diabetes. 2021;12(5):514\u201323. https:\/\/doi.org\/10.4239\/wjd.v12.i5.514.","journal-title":"World J Diabetes"},{"key":"1230_CR146","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4328954","volume":"2018","author":"R Hoff","year":"2018","unstructured":"Hoff R, Koh C-K. Isoproterenol induced insulin resistance leading to diabetic ketoacidosis in type 1 diabetes mellitus. Case Rep Endocrinol. 2018;2018:4328954. https:\/\/doi.org\/10.1155\/2018\/4328954.","journal-title":"Case Rep Endocrinol"},{"issue":"6","key":"1230_CR147","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1253\/circj.CJ-17-0040","volume":"81","author":"G Kimura","year":"2017","unstructured":"Kimura G. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and stroke. Circ J. 2017;81(6):898. https:\/\/doi.org\/10.1253\/circj.CJ-17-0040.","journal-title":"Circ J"},{"issue":"3","key":"1230_CR148","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/dom.13126","volume":"20","author":"KM Hallow","year":"2018","unstructured":"Hallow KM, et al. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab. 2018;20(3):479\u201387. https:\/\/doi.org\/10.1111\/dom.13126.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"1230_CR149","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.jacc.2021.01.033","volume":"77","author":"M Packer","year":"2021","unstructured":"Packer M, et al. Empagliflozin in patients with heart failure, reduced ejection fraction, and volume overload: EMPEROR-reduced trial. J Am Coll Cardiol. 2021;77(11):1381\u201392. https:\/\/doi.org\/10.1016\/j.jacc.2021.01.033.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1230_CR150","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","volume":"141","author":"CD Mazer","year":"2020","unstructured":"Mazer CD, et al. Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease. Circulation. 2020;141(8):704\u20137. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044235.","journal-title":"Circulation"},{"issue":"4","key":"1230_CR151","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2215\/cjn.0000000000000362","volume":"19","author":"M Packer","year":"2023","unstructured":"Packer M. Alleviation of anemia by SGLT2 inhibitors in patients with CKD: mechanisms and results of long-term placebo-controlled trials. Clin J Am Soc Nephrol. 2023;19(4):531\u20134. https:\/\/doi.org\/10.2215\/cjn.0000000000000362.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"1230_CR152","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/ejhf.2409","volume":"24","author":"JP Ferreira","year":"2022","unstructured":"Ferreira JP, et al. Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-reduced. Eur J Heart Fail. 2022;24(4):708\u201315. https:\/\/doi.org\/10.1002\/ejhf.2409.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"1230_CR153","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1136\/jnnp-2016-314704","volume":"88","author":"KP Imprialos","year":"2017","unstructured":"Imprialos KP, et al. Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality? J Neurol Neurosurg Psychiatry. 2017;88(3):249\u201353. https:\/\/doi.org\/10.1136\/jnnp-2016-314704.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1230_CR154","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01520-w","volume":"21","author":"CKH Wong","year":"2022","unstructured":"Wong CKH, et al. Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study. Cardiovasc Diabetol. 2022;21(1):92. https:\/\/doi.org\/10.1186\/s12933-022-01520-w.","journal-title":"Cardiovasc Diabetol"},{"issue":"17","key":"1230_CR155","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.70091","volume":"28","author":"J Wang","year":"2024","unstructured":"Wang J, et al. Inhibition of sodium-glucose cotransporter-2 improves anaemia in mice and humans with sickle cell disease, and reduces infarct size in a murine stroke model. J Cell Mol Med. 2024;28(17):e70091. https:\/\/doi.org\/10.1111\/jcmm.70091.","journal-title":"J Cell Mol Med"},{"issue":"3","key":"1230_CR156","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/bcp.12687","volume":"80","author":"RB Iwere","year":"2015","unstructured":"Iwere RB, Hewitt J. Myopathy in older people receiving statin therapy: a systematic review and meta-analysis. Br J Clin Pharmacol. 2015;80(3):363\u201371. https:\/\/doi.org\/10.1111\/bcp.12687.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"1230_CR157","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017587","volume":"7","author":"Z Zhou","year":"2017","unstructured":"Zhou Z, et al. Statin-associated muscle symptoms (SAMS) in primary prevention for cardiovascular disease in older adults: a protocol for a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2017;7(9):e017587. https:\/\/doi.org\/10.1136\/bmjopen-2017-017587.","journal-title":"BMJ Open"},{"issue":"7","key":"1230_CR158","doi-asserted-by":"publisher","first-page":"585","DOI":"10.7326\/l20-0549","volume":"173","author":"E Brailovski","year":"2020","unstructured":"Brailovski E, Kim RB, Juurlink D. Rosuvastatin myotoxicity after starting canagliflozin treatment: a case report. Ann Intern Med. 2020;173(7):585\u20137. https:\/\/doi.org\/10.7326\/l20-0549.","journal-title":"Ann Intern Med"},{"key":"1230_CR159","doi-asserted-by":"publisher","DOI":"10.1530\/edm-20-0017","author":"F Gao","year":"2020","unstructured":"Gao F, Hall S, Bach LA. Myopathy secondary to empagliflozin therapy in type 2 diabetes. Endocrinol Diabetes Metab Case Rep. 2020. https:\/\/doi.org\/10.1530\/edm-20-0017.","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"1230_CR160","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9010022","author":"RM Turner","year":"2019","unstructured":"Turner RM, Pirmohamed M. Statin-related myotoxicity: a comprehensive review of pharmacokinetic, pharmacogenomic and muscle components. J Clin Med. 2019. https:\/\/doi.org\/10.3390\/jcm9010022.","journal-title":"J Clin Med"},{"issue":"6","key":"1230_CR161","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/17425255.2021.1921735","volume":"17","author":"PN Lalagkas","year":"2021","unstructured":"Lalagkas PN, et al. Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: pharmacological and clinical evidence. Expert Opin Drug Metab Toxicol. 2021;17(6):697\u2013705. https:\/\/doi.org\/10.1080\/17425255.2021.1921735.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"1230_CR162","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/cpdd.166","volume":"4","author":"D Devineni","year":"2015","unstructured":"Devineni D, et al. Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants. Clin Pharmacol Drug Dev. 2015;4(3):226\u201336. https:\/\/doi.org\/10.1002\/cpdd.166.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"2","key":"1230_CR163","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s12325-011-0098-x","volume":"29","author":"S Kasichayanula","year":"2012","unstructured":"Kasichayanula S, et al. Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Adv Ther. 2012;29(2):163\u201377. https:\/\/doi.org\/10.1007\/s12325-011-0098-x.","journal-title":"Adv Ther"},{"issue":"11","key":"1230_CR164","doi-asserted-by":"publisher","first-page":"973","DOI":"10.5414\/CP202117","volume":"52","author":"S Macha","year":"2014","unstructured":"Macha S, et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and simvastatin following co-administration in healthy volunteers. Int J Clin Pharmacol Ther. 2014;52(11):973\u201380. https:\/\/doi.org\/10.5414\/CP202117.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"1230_CR165","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/cpdd.472","volume":"8","author":"VK Dawra","year":"2019","unstructured":"Dawra VK, et al. Assessment of the drug interaction potential of ertugliflozin with sitagliptin, metformin, glimepiride, or simvastatin in healthy subjects. Clin Pharmacol Drug Dev. 2019;8(3):314\u201325. https:\/\/doi.org\/10.1002\/cpdd.472.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"8","key":"1230_CR166","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1111\/bcp.15711","volume":"89","author":"CA Gravel","year":"2023","unstructured":"Gravel CA, et al. Concomitant use of statins and sodium-glucose co-transporter 2 inhibitors and the risk of myotoxicity reporting: a disproportionality analysis. Br J Clin Pharmacol. 2023;89(8):2430\u201345. https:\/\/doi.org\/10.1111\/bcp.15711.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1230_CR167","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40264-022-01166-3","volume":"45","author":"W Alkabbani","year":"2022","unstructured":"Alkabbani W, et al. Drug-drug interaction of the sodium glucose co-transporter 2 inhibitors with statins and myopathy: a disproportionality analysis using adverse events reporting data. Drug Saf. 2022;45(3):287\u201395. https:\/\/doi.org\/10.1007\/s40264-022-01166-3.","journal-title":"Drug Saf"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01230-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01230-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01230-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:12:21Z","timestamp":1762884741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01230-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":167,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1230"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01230-3","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"13 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent\u00a0to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"All data used in this review are available from the respective cited studies.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Yiwei Huang established the theme and scope of the review, systematically synthesized relevant literature, and drafted the initial manuscript. Xinyuan Yu contributed original insights and critical analysis, providing meticulous revisions that enhanced the depth of the discussion. Changxin Li offered valuable suggestions and conducted thorough revisions, ensuring linguistic fluency and adherence to formatting standards. All authors reviewed and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}